Lantern Pharma Inc. (LTRN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LTRN
- Company Lantern Pharma Inc.
- Price $1.71
- Changes Percentage -11.4
- Change -0.22
- Day Low $1.71
- Day High $1.93
- Year High $4.7
- Year Low $1.11
- Market Cap $29,856,402
- Price Avg 50 EMA (D) $3.17
- Price Avg 200 EMA (D) $2.99
- Exchange NASDAQ
- Volume 184,560
- Average Volume 156,930
- Open $1.93
- Previous Close $1.93
- EPS -1.62
- PE -1.44
- Earnings Announcement 2026-11-11 12:00:00
- Shares Outstanding $12,759,146
Company brief: LANTERN PHARMA INC. (LTRN )
- Healthcare
- Biotechnology
- Mr. Panna Sharma PH.D.
- https://www.lanternpharma.com
- US
- N/A
- 06-11-2020
- US51654W1018
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.